TY - JOUR T1 - Factor associated with global mortality in COPD between 2006 and 2011: French claims data JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P4719 AU - Laurent Laforest AU - Cheikh Tamberou AU - Marine Ginoux AU - Chu-Philippe Ya AU - Gilles Devouassoux AU - Nicolas Roche AU - Christos Chouaid AU - Eric Van Ganse Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P4719.abstract N2 - Background: A good understanding of prognostic factors of death in COPD may contribute to improve disease management. The role of patient and management-related factors during a baseline period on global mortality during the following years was investigated in COPD.Methods: A cohort of patients aged≥45, with documented follow-up and ≥3 dispensations in 2005 of a same drug-class were selected in French Claims data. Drug classes were long-acting beta agonists, short-acting beta agonists (SABAs), short-acting muscarinic antagonists (SAMAs), xanthines, and SAMA/SABA fixed combinations. Cox multivariate models were used to predict global 2006-2011 mortality. Analyzed co-factors were age, gender, dispensing level inhaled bronchodilatator therapy in 2005, free-access-to-care status, long-term-disease status (diabetes, respiratory, cardiovascular, tumoral, and mental diseases) and COPD-related hospitalization in 2005 (1-10, >10 days).Results: The mean annual death rate between 2006 and 2011 of the 4,800 patients (mean age 66, 50% women) was 4.6%. The strongest predicting factors was duration of COPD-related hospitalizations in 2005 (HR=2.0 and 2.3 for hospital stays of 1-10 days and >10 days, respectively), long-term disease status of cancer (HR=1.8), cardiovascular diseases (HR=1.3) and male gender (HR=1.7), p<0.0001 for all. Significant effects were also observed with long-term disease status for mental disorders (p=0.0004), severe respiratory condition (p=0.003) and diabetes (p=0.02).Conclusions: In this cohort of COPD patients, severe exacerbations for COPD in 2005 were the most prominent risk factor of death between 2006 and 2011. Comorbidities also markedly impacted COPD global mortality. ER -